A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : bRFS / biochemical relapse-free survival

[Related PubMed/MEDLINE]
Total Number of Papers: 147
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   bRFS  (>> Co-occurring Abbreviation)
Long Form:   biochemical relapse-free survival
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 A Recursive Partitioning Analysis Demonstrating Risk Subsets for 8-Year Biochemical Relapse After Margin-Positive Radical Prostatectomy Without Adjuvant Hormone or Radiation Therapy. GG, ME, PC, PSA, RP
2021 Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. OS, PCa, SIB
2021 Heuristic estimation of the alpha/beta ratio for a cohort of Mexican patients with prostate cancer treated with external radiotherapy techniques. BED, OTT, PCa, RT
2021 High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. BRT, GI, GU, HDR, NCCN, PCa
2021 How Has Prostate Cancer Radiotherapy Changed in Italy between 2004 and 2011? An Analysis of the National Patterns-Of-Practice (POP) Database by the Uro-Oncology Study Group of the Italian Society of Radiotherapy and Clinical Oncology (AIRO). EBRT, IGRT, IMRT, POP, RT
2021 Hypofractionated versus conventionally fractionated image-guided volumetric-modulated arc radiotherapy for localized prostate cancer: a phase II randomized trial from China. CFRT, GI, GU, HFRT, IG
2021 Identification and Validation of a PPP1R12A-Related Five-Gene Signature Associated With Metabolism to Predict the Prognosis of Patients With Prostate Cancer. DFS, GEO, GSEA, PCa, PPP1R12A
2021 Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study. GI, GU, OS, PCSS, RFS, SIB-IMRT
2021 OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. ADTs
10  2021 Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET. ADT, CI, HR, MDT, OM, PET/CT, PSA
11  2021 Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years. CTCAE, MFS, SBRT
12  2021 Ten Year Results of Extensive Nodal Radiotherapy and Moderately Hypofractionated Simultaneous Integrated Boost in Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer. ADT, DFS, OS, PCSS
13  2021 Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis. ADT, EBRT, FFM, GI, GU, HDR-BT boost, OS
14  2020 A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. CI, EBRT, EQD2, GI, GU, LC, re-RT
15  2020 Biochemical relapse free survival rate in patients with prostate cancer treated with external radiotherapy: outcomes obtained at the CMN Siglo XXI Hospital de Oncologia, CMN 20 de Noviembre and Hospital General de Mexico of the Mexico City. HGM, IMRT
16  2020 Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer. ADT, DMFS, LN, RFS, RT
17  2020 Impact of Concomitant Medications on Biochemical Outcome in Localised Prostate Cancer Treated with Radiotherapy and Androgen Deprivation Therapy. ADT, PCa
18  2020 Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer. BT, PCa, PP
19  2020 Linac-based SBRT as afeasible salvage option for local recurrences in previously irradiated prostate cancer. GI, GU, PC, PFS, RT
20  2020 Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity. GI, GU, iPSA, ISUP, mPFS, nPSA, OS, PC, PS, SBRT, TURP
21  2020 Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Oligo-PCa, OS
22  2020 Long-term outcomes of a prospective randomized trial of 131Cs/125I permanent prostate brachytherapy. 131Cs, BT
23  2020 Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. DMFS, MHRT, OS, PC, RT, VMAT
24  2020 Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis. IG-IMRT, IMRT, PSS, SIB
25  2020 Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation. CONV FR, CSS, GI, GU, HYPO FR, OS, PCa, RT, SIB
26  2020 Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial. ADT, EBRT, nmCRPC, PCa
27  2020 Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. LN, LR, MDT, ORPC, PSMA-PET, RPA, VM
28  2020 Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. BT, HDR
29  2020 Stereotactic body radiotherapy for localized prostate cancer - 5-year efficacy results. ADT, DSS, OS, PCa, SBRT
30  2019 125I low-dose-rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer. BF, cRFS, LDR, RP
31  2019 Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. ADT, cRFS, cRP, CRP, mPCA, OS, PSA, RP
32  2019 Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis. PBRT, SRT, WPRT
33  2019 Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). CI, DMFS, EBRT, GLUT1, HDR-BTb, HIF1alpha, HR, MVD, OPN
34  2019 MRI-Derived Radiomics to Guide Post-operative Management for High-Risk Prostate Cancer. ART, BCR, PCa
35  2019 Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer. BCR, mpMRI, RP, SRT
36  2019 Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer. ADT, PC, RT
37  2019 Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial. ADT, LPCa, OS, PRT, RT
38  2019 The association of intraprostatic calcifications and dosimetry parameters with biochemical control after permanent prostate implant. IC, PIPB
39  2019 The role of radical prostatectomy and definitive external beam radiotherapy in combined treatment for high-risk prostate cancer: a systematic review and meta-analysis. ADT, CI, CSS, EBRT, HRs, OS, PCa, RCT, RP
40  2019 Treatment outcomes of prostate cancer patients with Gleason score8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study. AJCC, DMFS, EBRT, GS, OS, PCa
41  2019 Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter? GI, GU, OTT, PCa, RT
42  2019 Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of 125I brachytherapy and robot-assisted radical prostatectomy. BT, CI, GI, GU, MRI, PSA, RARP, TTMB
43  2018 A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes. GS, GU, LDR, OS, TURP
44  2018 Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial. ADT, IGRT, LN, SIB, WPRT
45  2018 Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer. IMRT
46  2018 Long-term outcomes of proton therapy for prostate cancer in Japan: a multi-institutional survey of the Japanese Radiation Oncology Study Group. PT
47  2018 Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer. GI, GU, MH-IMRT
48  2018 Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival. BED, J-POPS, OS, PSA
49  2018 Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database. ADT, CSS, DFS, EBRT, FIR, GI, GU, IR, MIR, OS, PCa, PPBC, PSA, UIR
50  2018 Permanent seed implant brachytherapy in low-risk prostate cancer: Preoperative planning with 145 Gy versus real-time intraoperative planning with 160 Gy. IoP, PP
51  2018 Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review. GI, GU, HFRT, LC, OS, PCa
52  2018 Prognostic impact of nodal relapse in definitive prostate-only irradiation. DMFS, DSS, OS, PNRFS, POI
53  2018 Salvage radiation therapy after radical prostatectomy: survival analysis. cRFS, DMFS, IMRT, MVA, PCSS, pGS, pT, SRT, UVA
54  2017 11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. CTCAE, HTT, LNs, OS, PCa
55  2017 A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer. ADT, cRFS, EBRT, HRCaP, LDR, PCSM, RP
56  2017 A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. MFS, PCs, PCSS
57  2017 Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database. ART, PCa, RP, SRT
58  2017 Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. ADT, bGS, DMFS, EBRT, FHR, HR, NCCN, PSA, UHR
59  2017 Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience. PCa, SBRT
60  2017 Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System. IO-LDRB
61  2017 Postoperative radiotherapy for prostate cancer: the sooner the better and potential to reduce toxicity even further. 3DCRT, ADT, ART, BEDVHs, DVHs, OS, SRT, VMAT-IGRT
62  2017 Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure? PCa, SBRT
63  2017 Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer. EBRT, PSA, rSBRT
64  2017 Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes. EBRT, IIEF, IPSS, PC, SBT
65  2017 [Stereotactic Body Radiotherapy of Prostate Cancer - Effectiveness and Toxicity]. OS, SBRT
66  2016 A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy. HDRB, PC, SBRT
67  2016 Hypofractionated Volumetric Modulated Arc Radiotherapy with simultaneous Elective Nodal Irradiation is feasible in prostate cancer patients: A single institution experience. ADT, ENI, FU, OC, PTV, SIB, VMAT, WPRT
68  2016 Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. CI, GU, HIMRT, PSA, RT
69  2016 Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. CSS, EQD2, MVCT
70  2016 Outcomes for prostate glands >60 cc treated with low-dose-rate brachytherapy. CI, GU
71  2016 Posttreatment Prostate-Specific Antigen 6Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality. ADT, DMFS, EBRT, HR, iPSA, MVA, PCa, PCSM, PSA
72  2016 Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy. ART, cRFS, GS, HR, IR, LR, OS, PSA, RF
73  2015 Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter? ADJ, ADT, DMFS, NEO, OS, RT
74  2015 Combination of adjuvant radiotherapy and androgen deprivation therapy after radical prostatectomy in high risk prostate cancer patients - results from retrospective analysis. ADT, ART, DSS, LHRH, LNI, LVI, mFS, OS, PCa, PSA, RP
75  2015 Comparison of permanent (125)I seeds implants with two different techniques in 500 cases of prostate cancer. BF, PSA
76  2015 Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis. PBRT, RP, SRT, WPRT
77  2015 Long-Term Efficacy and Toxicity of Low-Dose-Rate ⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer. DMFS, GI, GU, OS, PCSM, PI
78  2015 Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is 11C-Choline PET/CT Predictive of Survival Outcomes? cRFS, HTT, LN, MTV, MTV60, PCa, ROC
79  2014 Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG. EPE, GS, SVI
80  2014 Assessment of the American Joint Committee on Cancer 7th edition staging for localised prostate cancer in Asia treated with external beam radiotherapy. AJCC, AJCC7, MVA, OS, PCa, UVA
81  2014 Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. BF, cRFS, CSS, nPSA, OS, RP, SRT
82  2014 Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system. AEs, CT, CTV, IMRT, PTV, RTRT
83  2014 External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer. ADT, CI, CSS, EBRT, HDRB, OS, pts
84  2014 Outcome of postoperative radiotherapy following radical prostatectomy: a single institutional experience. OS
85  2014 Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases. COMB, DSS, OS, PSA, PSI
86  2014 Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis. CTCs, DFS, DTCs, HR, OS
87  2014 PSA response to neoadjuvant androgen deprivation is an independent prognostic marker and may identify patients who benefit from treatment escalation. ADT, HR, PSA, RT
88  2014 Results of Dose-adapted Salvage Radiotherapy After Radical Prostatectomy Based on an Endorectal MRI Target Definition Model. erMRI, RP, SRT
89  2014 Stereotactic body radiation therapy for prostate cancer patients with old age or medical comorbidity: a 5-year follow-up of an investigational study. OS, PFS, PSA, SBRT
90  2013 Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy). 3DCRT, AHT, EBRT, HDR, NHT
91  2013 Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. AD, OM, RT
92  2013 Dose-escalated salvage radiotherapy after radical prostatectomy in high risk prostate cancer patients without hormone therapy: outcome, prognostic factors and late toxicity. cRFS, PSRM, RP, SRT
93  2013 Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK. LDR, PSA
94  2013 Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. ADT, SBRT
95  2012 Analysis of survival in radical and postoperative radiotherapy for prostate cancer. 3DCRT, AWD, DOC, DOD, HT, post-op, RT
96  2012 Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy. GST, GSTs, HR, PCa, RRP
97  2012 [Incidence and prognostic factors for biochemical recurrence after radical radiotherapy]. ADT, BR
98  2011 High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. AD, cRFS, HD-SIMRT, HR, IMRT, PSA, RP, SRT
99  2011 Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml. PSA, RP, RT
100  2011 Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. ADT, bGS, DMFS, EBRT, FHR, HR, PCSM, PSA, UHR